BioSpace News Archive

Edwards Lifesciences reported financial results for the quarter ended June 30, 2022.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th , 2022, on Thursday, August 4th , 2022, after the close of the US market.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022.

Viveve Medical, Inc., a medical technology company focused on women’s health and the treatment of stress urinary incontinence, announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022.

The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions and services, reported net income of $64 million for the quarter ended June 30, 2022, a 15% increase over the prior year.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022.